Bristol-Myers Squibb and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, expanded their relationship today by announcing a three-year collaboration agreement. 2 May 2018
China and USA-based oncology specialist BeiGene has appointed Xiaobin Wu as general manager of China and president of the company, reporting to the CEO. 2 May 2018
Tech industry veteran Joanna Shields, who since 2016 has been UK Prime Minister Theresa May’s Special Representative on Internet Safety, has been named the new chief executive of BenevolentAI, an artificial intelligence (AI) company focused on health and drug development. 2 May 2018
US drugmaker AbbVie has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis. 1 May 2018
The US Food and Drug Administration has accepted for review a supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, based on results of the Phase III KEYNOTE-189 trial. 1 May 2018
AstraZeneca has reportedly been given a positive recommendation from the Japanese health ministry for its PD-L1 inhibitor Imfinzi (durvalumab). 27 April 2018
French biotech firm Adocia has entered into a strategic partnership with Tonghua Dongbao Pharmaceuticals, granting the Chinese firm exclusive development and commercialization rights to the BioChaperone Combo and ultra-rapid insulin BioChaperone Lispro in China and other designated areas. 27 April 2018
Chugai Pharmaceutical, which is majority-owned by Swiss pharma giant Roche, has filed an application for expanded use of its anti-coagulation factor IXa/X humanized bispecific monoclonal antibody/coagulation factor VIII substitute, Hemlibra (emicizumab) subcutaneous injection. 27 April 2018
Swiss pharma giant Novartis says that it has filed its chimeric antigen receptor T cell (CAR-T) therapy tisagenlecleucel, known as Kymriah overseas, for certain types of leukemia and lymphoma, marking the first CAR-T submission in Japan. 24 April 2018
Two Chinese firms, drugmaker Simcere Pharmaceutical and biotech HitGen, have finalized a license deal, expanding on a previous agreement to discover and develop novel therapies. 24 April 2018
Sino-American biotech CBT Pharmaceuticals is to collaborate with South Korea’s CrystalGenomics to develop an investigational combination therapy of CBT-501 and CG200745 in solid tumors. 24 April 2018
In the ongoing saga of Takeda’s pursuit of Ireland-headquartered rare diseases specialist Shire, which had already rejected three separate bids from the Japanese pharma major, a fourth one was revealed after London markets closed on Friday. 21 April 2018
Japan’s Chugai Pharmaceutical has launched Tecentriq (atezolizumab, an intravenous Infusion) recombinant humanized anti-PD-L1 monoclonal antibody, (1200 mg) for the treatment of “unresectable advanced or recurrent non-small cell lung cancer (NSCLC), marking the debut of the PD-L1 class in Japan’s lung cancer space. 19 April 2018
Japan’s Astellas Pharma and Kite, a Gilead Sciences subsidiary today announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. 18 April 2018
Switzerland’s regulator has followed in the footsteps of the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada and Australia’s Therapeutic Goods Administration by accepting Shire’s submission for lanadelumab. 18 April 2018
The Food and Drug Administration has provided full approval for Praxbind (idarucizumab), the specific reversal agent for Pradaxa (dabigatran etexilate mesylate). 17 April 2018
US pharma major Eli Lilly’s Lartruvo (olaratumab) is the first medicine to be granted a provisional approval determination under the new provisional approval pathway which came into effect on March20, 2018, Australian regulator the Therapeutic Goods Administration (TGA) announced today. 16 April 2018
French biotech firm Inventiva have announced a successful fundraising round totalling $44 million, the largest portion of which will be invested in efforts to combat nonalcoholic steatohepatitis (NASH), a severe liver disease. 13 April 2018
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024